|
DEPRAX®
inyectable
Trazodone
Broad-spectrum antidepressant
Deprax®
is comprised of trazodone hydrochloride, a molecule with a potent antidepressant
action, which differs from the usual antidepressants in its biochemical
structure and its mechanism of action.
According to biochemical and neurophysiological data, the site of action
of Deprax® is the diencephalic structures that control and organise
the emotional and affection sphere, and whose primitive or secondary alteration
represents a common pathogenic stage of depression and its somatic equivalences.
COMPOSITION
Each ampoule contains:
Trazodone (INN) HCl................................................................................
50 mg
Excipients: sodium chloride, water for injectable solutions, q.s. 5 ml.
THERAPEUTIC
INDICATIONS
Psychiatric: Organic, endogenous, psychogenic, symptomatic and
involutional depressions. Mixed stages of depression with anxiety. Atypical
or masked depressions (psychosomatic disorders).
Neurological: Tremors, dyskinesias.
Geriatric: Emotional-affective and behavioural disorders: irritability,
aggressiveness, emotional lability, apathy, tendency towards isolation,
reduction in sleep time.
Surgical: Pre-anaesthetic, pre-endoscopic and postoperative medication.
POSOLOGY
Dosage will be adapted to the needs and to the response of each patient,
beginning at low doses that may be increased progressively to suitable
levels, beginning preferably at night.
In very severe depressions, 2 to 4 ampoules of Deprax® inyectable
(100 to 200 mg) diluted in 250 to 500 ml of saline or glucose solution
on a slow endovenous drip, twice daily.
After 10 to 14 days of endovenous therapy treatment should continue with
300 to 600 mg daily, in 3 to 6 takes, by oral administration. In pre-anaesthesia,
diagnostic instrumentation and postoperative medication, 1 intramuscular
or slow endovenous solution for injection 1 or 2 twice a day.
INSTRUCTIONS
FOR USE
During slow endovenous perfusion (20 to 40 drops per minute) and for up
to one hour after, the patient should remain in the supine position, as
a slight drop in blood pressure may take place.
CONTRAINDICATIONS
AND PRECAUTIONS
Proceed with caution in cases of decompensated heart failure and hypotension.
During the first week of treatment it may affect the capacity to drive
vehicles or use precision machinery.
Do not use during the first three months of pregnancy.
INCOMPATIBILITIES
There are no incompatibilities. Nevertheless, the patient should be monitored
if the treatment is combined with other psychopharmaceuticals, as well
in treatments with antihypertensives.
UNDESIRABLE
EFFECTS
In some cases drowsiness, asthenia, hypotension, headache, vertigo, mild
excitation, dryness of mouth, psychomotor and gastrointestinal disorders
may appear. Generally speaking, these effects are transient and do not
require interruption of the treatment.
As occurs with other drugs with alpha-adrenolytic activity, rare cases
of priapism associated with treatment with trazodone have been reported.
In this case the patient should stop the treatment rapidly.
OVERDOSE
In case of overdose, symptomatic treatment with analeptics, gastric lavage
and forced diuresis should be initiated.
In case of overdose or accidental intake, call the Toxicology Information
Service on 91 562 04 20.
PRESENTATION
Box with 10 ampoules of 50 mg.
Clinical container: box with 100 ampoules of 50 mg.
Other
presentations
Box with 30 tablets of 50 mg.
Boxes with 30 and 60 tablets of 100 mg.
Clinical container: box with 1,000 tablets of 100 mg.
BY PRESCRIPTION ONLY
Keep
medicines out of the reach of children.
Farma-Lepori,
S.A.
C. Osi, 7- 08034 Barcelona
top
|
